Seagen touts full PhII Tukysa da­ta as it plots col­orec­tal can­cer ex­pan­sion

As ru­mors of a Mer­ck buy­out con­tin­ue to swirl around Seagen, the big Seat­tle biotech is charg­ing ahead with new da­ta for its can­cer drug Tukysa.

Seagen re­port­ed full re­sults Sat­ur­day from a Phase II study mea­sur­ing Tukysa’s ef­fec­tive­ness in sec­ond-line HER2-pos­i­tive metasta­t­ic col­orec­tal can­cer, af­ter re­veal­ing a 38.1% over­all re­sponse rate in May. The new da­ta show Tukysa, in com­bi­na­tion with Her­ceptin, in­duced a pro­gres­sion-free sur­vival of 8.2 months and over­all sur­vival of 24.1 months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.